Sharps Technology, Inc. ("Sharps" or the "Company"), a medical device sales and distribution company that has adopted a Solana-based digital asset treasury strategy, has announced financial results for the year ended December 31, 2025, and provided an update on the continued execution of its treasury and infrastructure strategy.

The Company entered 2025 as a capital-constrained medical device manufacturer and exited 2025 with what management believes is the strongest financial and strategic platform in the Company's history. In a matter of months, Sharps launched a Solana-focused digital asset treasury strategy, accumulated more than 2 million SOL, established a recurring staking income stream with ~95% of our SOL actively staked at a ~7% gross annualized yield, eliminated unprofitable manufacturing overhead, restored positive working capital, substantially expanded stockholders' equity, and repositioned the Company around a far more scalable and capital-flexible operating model.

"Our 2025 year-end results reflect a pivotal transition for Sharps Technology," said Paul K. Danner, Executive Chairman. "During the year, we transformed the Company's balance sheet, completed our strategic shift away from unprofitable legacy operating activities, established a treasury position of more than 2 million SOL, and laid the foundation for a more scalable and capital-efficient platform. As we move through 2026, we intend to build on a foundation that simply didn't exist a year ago to grow the Company's business."

With legacy manufacturing activities being phased out and a sizable SOL treasury now in place, Sharps believes it is operating from a position of substantially greater strength than a year ago. The Company is focused on maximizing staking economics across its treasury, leveraging institutional-grade counterparties and infrastructure, and deploying its balance sheet in ways management believes can accelerate long-term value creation.

Key highlights from 2025 and recent developments:

  • As of December 31, 2025, the Company held over 2 million SOL with approximately 95% actively staked.
  • The Company had total revenue of approximately $7.0 million for FY 2025, including $6.8 million in net staking revenue, which represented an approximately 7% gross annualized validator staking yield, and $204,120 in product revenue from medical device distribution.
  • The Company exited FY 2025 with total assets of $269.1 million (up from $7.3 million at year-end 2024), including $250.1 million in digital assets at fair value, $10.4 million in cash, and positive working capital of $14.2 million. Stockholders' equity grew to $264.4 million (from $2.0 million at year-end 2024), while total liabilities declined to $4.7 million. The notes payable balance of $3.8 million at year-end 2024 was fully eliminated.
  • The Company launched its Sharps-branded validator through Coinbase's institutional infrastructure and expanded strategic partnerships across the Solana ecosystem, including collaborations with Crypto.com, BitGo, Jupiter Exchange, The Tie, Bonk, and Pudgy Penguins.
  • The Company raised over $430 million in total capital during FY 2025 through equity offerings and warrant exercises, including cash, digital asset, and stablecoin contributions, funding the Company's rapid SOL accumulation and treasury buildout.